Item 1.01. Entry into a Material Definitive Agreement.
On May 28, 2021, Dyadic International (USA), Inc., a subsidiary of Dyadic
International, Inc., (hereinafter collectively referred to as "Dyadic" or the
"Company") entered into an amendment to its Master Services Agreement (the
"Amended MSA") with CR2O B.V. ("CR2O"), which was previously signed on March 18,
2021. The Amended MSA restated the Company's engagement with CR2O to oversee and
perform certain pre-clinical and clinical trial services related to the
Company's C1 produced SARS-CoV-2 receptor binding domain (RBD) of the SARS-CoV-2
spike protein COVID-19 vaccine candidate ("DYAI-100") which the Company is
moving towards an anticipated Phase 1 clinical trial. The Amended MSA also
included Work Order Number 02 between the Company and CR2O, also dated May 28,
2021, where CR2O will continue oversee and perform additional pre-clinical trial
services relating to the Company's COVID-19 DYAI-100. The Amended MSA is
effective retroactively on March 18, 2021 (the Effective Date") and the term of
the MSA remains for a period of five (5) years from the Effective Date.
The foregoing description of the MSA and the Work Order is qualified in its
entirety by reference to the complete terms and conditions of the MSA and the
Work Order, which are filed as Exhibit 10.1 to this Current Report on Form 8-K
and incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits
The following exhibit is being furnished herein:
10.1 Master Services Agreement and Work Order, between Dyadic
International (USA), Inc. and CR2O B.V., Dated May 28, 2021.
Specific items in this exhibit have been redacted, as market
by three asterisks[***].
104 Cover page Interactive Data File (embedded within the Inline
© Edgar Online, source Glimpses